ASICS
30.3.2022 01:03:11 CEST | Business Wire | Press release
Today, the impact of physical inactivity on our mental state has been revealed for the first time in the Mind Racei – an ASICS experiment in which regular exercisers paused their normal fitness routines for one week. The impact on their state of mind was found to be similar to a week of broken sleepii , with participants reporting a 23% increase in racing thoughts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220329005848/en/
Reassuringly, the results of ASICS’ Uplifting Minds Studyiii , involving thousands of participants from across the globe, proves it can take just 15:09 minutes of physical activity to lift our mental state – even after periods of inactivity.i
The Mind Race: just one week of inactivity significantly lowers our state of mind
Professor Brendon Stubbs, a leading researcher in movement and the mind, monitored the State of Mindiv scores of healthy participantsv who agreed to pause their regular exercise routines for just one week. The results are significant with both their cognitive and emotional wellbeing being impacted. When active people stopped moving, their confidence dropped by 20%; positivity fell by 16%, energy levels slumped by 23% and their ability to cope with stress reduced by 22%.
In fact, after just one week of no exercise, participants’ overall State of Mind score dropped by an average of 18% - decreasing from a high 68 out of 100 when physically active to a mediocre 55 out of 100 when they stopped exercising. The effects of this inactivity are captured in the Mind Race experiment film asics.com/mindrace , following a group of study participants.
Just 15 minutes of activity can uplift our state of mind
But there is good news. Participants were monitored when they returned to their regular exercise regime and all experienced immediate improvements in their state of mind – showing how quickly the negative effects of inactivity can be reversed. Professor Brendon Stubbs also analysed data from thousands of people who participated in ASICS' ongoing Uplifting Minds Study since June 2021. The Study uses cutting edge technology to mimic EEG and capture the impact of exercise on people’s state of mind. Based on data from across sports and across regions, just 15.09 minutes of exercise can significantly impact our mental state.
Commenting on the results, Professor Brendon Stubbs said: “We know that exercise is good for our mental health but the impact of rest and restarting exercise is less clear. Now, thanks to new technology and the contribution of thousands of people, we’ve been able to pinpoint just how much exercise is needed to trigger a positive mental impact. This ASICS study helps to quantify the amount of exercise to improve mental health and make it more tangible. Taking time to rest is very important. This study shows that people’s wellbeing bounces back very quickly after a period of rest when people resume regular exercise again.”
Gary Raucher, EVP, ASICS EMEA said: “Our founding philosophy is literally in our name, Anima Sana In Corpore Sano or a Sound Mind in a Sound Body. And we believe our focus on the benefits of sport and movement, not just on the body, but also on the mind, has never been more relevant. We know the last two years have been tough on the mental state of many. And while not the answer for everyone, we know exercise can make a difference. We hope to inspire more people to move with ASICS, even for just 15.09 minutes to feel the benefits on body and mind.”
To be part of ASICS’ ongoing Uplifting Minds Study and see the impact of exercise on your own State of Mind, visit https://minduplifter.asics.com/
Notes to Editors
Download imagery
Watch video link
For further information, images or to organize an interview with Professor Brendon Stubbs, please contact Asics@Golin.com
ASICS’ Uplifting Minds Study enables people all over the world to measure the impact of movement on their mind. Using cutting edge facial scanning technology and self-reported data, ASICS has measured the impact of exercise on thousands of minds from 79 countries over a 10-month period.
ASICS’ Mind Race, a three-week extension of the study, measured what happened to the minds of 58 regular exercisers from 21 countries when they stopped exercising for just one week. Using self-reported data, qualitative questionnaires and cutting-edge technology, the study pinpointed the effects of both physical activity and inactivity on participants mental wellbeing.
___________
i
ASICS’ Mind Race Study 2022
ii
Comparison drawn from Soomi Lee, Naturally Occurring Consecutive Sleep Loss and Day-to-Day Trajectories of Affective and Physical Well-Being, Annals of Behavioral Medicine, 2021, DOI: 10.1093/abm/kaab055
iii
ASICS’ Uplifting Minds Study 2021-2022
iv
ASICS proprietary State of Mind score is a rating out of 100 made up of 10 emotional and cognitive metrics, including: composure, resilience, positivity, contentment, relaxation, confidence, alertness, calmness, focus and energy.
v
Volunteers who passed the screening criteria and consented to participate. Screening criteria included: adults (age 18+), already physically active (doing more than 150 minutes of moderate to vigorous exercise per week) and willing to stop exercising for one week with the belief it would not have a detrimental impact on their mental health.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005848/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
